ストックスクリーナーアプリを入手
0.8127
9.01%
0.0672
アフターアワーズ：
.82
0.0073
+0.90%
前日終値:
$0.7455
開ける：
$0.7621
24時間の取引高:
1.40M
Relative Volume:
1.22
時価総額：
$103.63M
収益：
-
当期純損益:
$-25.91M
株価収益率:
-3.2288
EPS:
-0.2517
ネットキャッシュフロー:
$-22.73M
1週間 パフォーマンス:
-3.62%
1か月 パフォーマンス:
-2.55%
6か月 パフォーマンス:
-17.41%
1年 パフォーマンス:
-36.51%
1日の値動き範囲:
$0.7556
$0.8501
1週間の範囲:
$0.7305
$0.8501
52週間の値動き範囲:
$0.7301
$1.51
Oncolytics Biotech Inc Stock (ONCY) Company Profile
名前
Oncolytics Biotech Inc
セクター
電話
(403) 670-7377
住所
SUITE 325, 4350 EXECUTIVE DRIVE, SAN DIEGO, AB
Compare ONCY vs VRTX, REGN, ARGX, MRNA, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ONCY
Oncolytics Biotech Inc
|
0.8127 | 95.06M | 0 | -25.91M | -22.73M | -0.2517 |
VRTX
Vertex Pharmaceuticals Inc
|
519.51 | 130.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
793.74 | 80.46B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
990.54 | 61.58B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
146.69 | 57.48B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
205.11 | 43.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Oncolytics Biotech Inc Stock (ONCY) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-08-13 | 開始されました | Lake Street | Buy |
| 2022-10-06 | 開始されました | Maxim Group | Buy |
| 2021-02-17 | 開始されました | H.C. Wainwright | Buy |
Oncolytics Biotech Inc (ONCY) 最新ニュース
ONCY Stock Heads For Sixth Straight Session Of Gains – Lead Therapy Shines in Early Combination Treatment Study - Stocktwits
Oncolytics Biotech Stock Price Forecast. Should You Buy ONCY? - StockInvest.us
Neonc Technologies Holdings, Briacell Therapeutics and Oncolytics Biotech Have Report Clinical and Regulatory Developments Across Brain, Breast and Colorectal Cancer - marketscreener.com
symbol__ Stock Quote Price and Forecast - CNN
Oncolytics Biotech Inc - Baystreet.ca
Oncolytics (ONCY) Reports Promising Preclinical Data on Pelareor - GuruFocus
Oncolytics reports preclinical data on pelareorep with RAS inhibitor - investing.com
Oncolytics reports preclinical data on pelareorep with RAS inhibitor By Investing.com - Investing.com India
An experimental cancer treatment combination reduced tumor growth in early tests - Stock Titan
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Oncolytics Biotech Inc.ADR Key Financial Ratios – Valuation, Profitability & More - Value Research
Zacks Research Issues Pessimistic Forecast for ONCY Earnings - MarketBeat
ONCY: FDA Provides Alignment on Registrational Pathway for Pelareorep in CRC - Yahoo Finance
Could Oncolytics Biotech (TSX:ONC) Reach Its Next Clinical Milestone? - Kalkine Media
Can Oncolytics Biotech (TSX:ONC) Unlock Its Next Catalyst? - Kalkine Media
HC Wainwright Has Bearish Estimate for ONCY FY2026 Earnings - MarketBeat
ONCY Maintained by HC Wainwright & Co. -- Price Target Lowered t - GuruFocus
Oncolytics Biotech (NASDAQ:ONCY) Price Target Cut to $5.00 by Analysts at HC Wainwright - MarketBeat
H.C. Wainwright cuts Oncolytics Biotech price target to $5 on pipeline shift - Investing.com Canada
H.C. Wainwright Maintains Oncolytics Biotech(ONCY.US) With Buy Rating, Cuts Target Price to $5 - Moomoo
Why Oncolytics Biotech Just Cleared A Hurdle That Stalls Most Cancer Trials - Yahoo Finance
BRIEF-Oncolytics Biotech® Aligns With FDA On Registrational Path For Second-Line Ras-Mutant Mss Colorectal Cancer - Bitget
Oncolytics Biotech (ONCY) Advances Pelareorep Trial with Positiv - GuruFocus
Stocks in play: Oncolytics Biotech Inc - Barchart.com
Form 8K Oncolytics Biotech Inc. For: 18 August By Investing.com - Investing.com Nigeria
Oncolytics receives FDA feedback on colorectal cancer study design - Investing.com
Oncolytics receives FDA feedback on colorectal cancer study design By Investing.com - Investing.com Canada
Oncolytics aligns with FDA on potential pivotal expansion of REO 033 in RAS‑mutant MSS colorectal cancer - TradingView
Oncolytics may seek accelerated approval using tumor response data - Stock Titan
Oncolytics Biotech (ONCY) Climbs 4.25% to $0.83 as Small-Cap Biotech Finds BuyersRetracement Entry - vinanet.vn
ONCY Q3 2025 Earnings: Wider Loss Misses Estimates, Stock Still Rises 4.25%Cost Structure Review - vinanet.vn
ONCY News | ONCOLYTICS BIOTECH INC (NASDAQ:ONCY) - ChartMill
Oncolytics Biotech (ONCY) Holds Near $0.82 as Shares Edge Up 0.49%Entry Point Alerts - vinanet.vn
Oncolytics Biotech (NASDAQ:ONCY) Announces Quarterly Earnings Results, Misses Estimates By $0.03 EPS - MarketBeat
ONCY: Net loss increased to $9.4M in Q2 2026, with cash needs exceeding current resources - TradingView
Oncolytics net loss widens to $9.44 million in Q2 2026; R&D expenses more than doubled to $4.26 million - Bitget
Oncolytics Biotech Inc (ONCY) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Oncolytics Biotech (ONCY) Expected to Post Quarterly Earnings on Friday - MarketBeat
Why Overall Survival May Be Becoming Oncology’s Most Important Metric (NASDAQ: ONCY) - Barchart.com
10-Q: Oncolytics Biotech | 10-Q: Q1 2026 Earnings Report - Moomoo
Oncolytics Biotech (NASDAQ:ONCY) Trading Up 0.2%Time to Buy? - MarketBeat
Oncolytics Biotech (ONCY) Slips 1.41% as Shares Approach Key Support at $0.70Swing Entry Signals - vinanet.vn
Oncolytics Biotech Inc (ONCY) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Weekly Recap: Pelareorep FDA Fast Track and Nasdaq sub-$1 notice - TradingView
Oncolytics Biotech Inc (ONCY) Balance Sheet - TradingKey
Oncolytics Biotech Inc (ONCY) Valuation: PE, PB & Fair Value Analysis - TradingKey
Oncolytics Biotech Inc (ONCY) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Oncolytics Biotech Inc (ONCY) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Oncolytics Biotech Inc (ONCY) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
ONCY|Oncolytics Biotech Inc|Price:0.810|Chg%:-0.002 - TradingKey
ONCY|Oncolytics Biotech Inc|Price:0.812|Chg%:-0.036 - TradingKey
Oncolytics Biotech Inc (ONCY) 財務データ
収益
当期純利益
現金流量
EPS
Oncolytics Biotech Inc (ONCY) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Kelly Jared | Chief Executive Officer |
Mar 12 '26 |
Buy |
0.96 |
5,050 |
4,848 |
114,050 |
| Kelly Jared | Chief Executive Officer |
Feb 12 '26 |
Buy |
0.84 |
29,500 |
24,839 |
109,000 |
| Kelly Jared | Chief Executive Officer |
Feb 11 '26 |
Buy |
0.84 |
5,600 |
4,682 |
79,500 |
| Look Kirk | Chief Financial Officer |
Feb 12 '26 |
Buy |
0.84 |
12,000 |
10,104 |
287,515 |
| Pisano Wayne | Director |
Feb 12 '26 |
Buy |
0.84 |
30,000 |
25,338 |
492,414 |
| Heineman Thomas Charles | Chief Medical Officer |
Feb 12 '26 |
Buy |
0.83 |
12,132 |
10,033 |
282,818 |
| Brown Deborah Margaret | Director |
Feb 12 '26 |
Buy |
0.85 |
25,000 |
21,240 |
109,851 |
| Hagerman Allison | VP, Product Development |
Feb 12 '26 |
Buy |
0.83 |
10,000 |
8,298 |
115,059 |
| Seizinger Bernd R. | Director |
Feb 11 '26 |
Buy |
0.83 |
60,000 |
49,590 |
526,991 |
| Seizinger Bernd R. | Director |
Feb 12 '26 |
Buy |
0.85 |
40,000 |
33,864 |
566,991 |
0.75%
3.18%
大文字化:
|
ボリューム (24 時間):